A prospective open labelled clinical trial to assess the role of Homoepathic medicines in Cholelithiasis

A prospective open labelled clinical trial to assess the role of Homoeopathic medicines in Cholelithiasis - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/093540

Enrollment

Registered

2025-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K80- Cholelithiasis

Interventions

Intervention1: Homoeopathic medicines: Indicated homoeopathic medicine as per symptom similarity would be selected on the basis of totality of symptoms, followed by repertorization. Selected medicine

Eligibility

Inclusion criteria

Inclusion criteria: ? Patient with or without symptoms of upper abdominal pain and tenderness, nausea, vomiting, jaundice, or other dyspeptic features but having evidence of gallstones (single or multiple) or gall bladder sludge with average diameter less than or equal to 15 mm or showing contracted GB or partially contracted GB in Upper abdominal USG.

Exclusion criteria

Exclusion criteria: Complicated Cholelithiasis i.e. for example cases which need immediate surgical intervention and complications like obstructive jaundice perforation fistula empyema gangrene carcinoma liver failure cholangitis gallstone ileus or pancreatitis or any related serious complications. Acute cholecystitis with ASA classification greater than III Cirrhosis of Liver Malignancy Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
To evaluate the response of homoeopathic medicines by comparing the assessing status of Cholelithiasis (absent or present/ if still present _ increased, decreased or status quo) and gall bladder thickness via Upper abdominal USG at baseline, 6 months and 12 months and also assessing the symptoms of the patient via GSS (Gall stone symptom score)16at baseline, 3 months, 6 months, 9 months and 12 months.Timepoint: Baseline 6month 12month	—

Measure

Time frame

To evaluate the response of homoeopathic medicines by comparing the assessing status of Cholelithiasis (absent or present/ if still present _ increased, decreased or status quo) and gall bladder thickness via Upper abdominal USG at baseline, 6 months and 12 months and also assessing the symptoms of the patient via GSS (Gall stone symptom score)16at baseline, 3 months, 6 months, 9 months and 12 months.Timepoint: Baseline 6month 12month

—

Secondary

Measure	Time frame
To assess the quality of life using The Gastrointestinal Quality of Life Index (GIQLI) 17which includes both specific questions on gastrointestinal symptoms, for both the upper and lower digestive tracts, as well as generic questions on physical, emotional, and social capabilities and also comparing the parameters of LFT and Lipid profile (at baseline, 6 months, 12 months).Timepoint: Baseline 6month 12month	—

Measure

Time frame

To assess the quality of life using The Gastrointestinal Quality of Life Index (GIQLI) 17which includes both specific questions on gastrointestinal symptoms, for both the upper and lower digestive tracts, as well as generic questions on physical, emotional, and social capabilities and also comparing the parameters of LFT and Lipid profile (at baseline, 6 months, 12 months).Timepoint: Baseline 6month 12month

—

Countries

India

Contacts

Public ContactDrPartha Pratim Pal

Central Council for Research in Homoeopathy

justdoit.partha007@gmail.com8910890779

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026